The ADC cytotoxic payloads and warheads market is thriving due to advancements in cancer therapies, involving chemical optimizations and linker technologies that boost therapeutic efficacy. Key ...
Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...
This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...
Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors. This is an ASCO Meeting ...
Receives Australian HREC Approval and CTN Clearance for First-in-Human StudySAN MATEO, Calif.--(BUSINESS WIRE)--#ADC--Kivu Bioscience, Inc., a clinical-stage biotechnology company developing ...
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...
New research published in Nature Communications has linked a normal cellular process to an accumulation of DNA mutations in cancer and identified cancer-driving mutations in an underexplored part of ...
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Heavily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results